US Market Access Shifts: Profit Warnings, New Approvals, and Policy Changes

Marcus"Welcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

Sara"And I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning. The market access landscape feels particularly volatile right now.

Marcus"Same here. We're looking at HCA's profit warning — what it signals about access erosion in US healthcare. Then subcutaneous Leqembi approval — how it reshapes the Alzheimer's value narrative. And the FTC-CVS insulin settlement — what it exposes about PBM practices. Finally, ICER's early-phase scientific advice expansion — how it aims to de-risk development.

Sara"That second one is interesting to me — the subcutaneous formulation changes the administration burden equation, but the value narrative for Alzheimer's remains incredibly complex for payers.

Marcus"Exactly. Let's get into it.

Sara"Let's start with HCA's profit warning. This isn't just a financial signal; it's a clear indicator of access challenges emerging in US healthcare systems. When one of the largest hospital operators issues such warnings, it suggests broader systemic pressures affecting patient access to innovative treatments.

Marcus"That's one read — I'd frame it slightly differently. This profit warning specifically references reimbursement pressures and payer pushback on high-cost therapies. What strikes me is that HCA explicitly mentions these challenges are impacting their ability to provide certain cutting-edge treatments, creating a direct link between financial performance and patient access.

Sara"The part that gives me pause is how this connects to broader market dynamics. When hospital systems struggle financially, they often tighten formularies or increase prior authorization requirements, creating downstream access barriers that aren't immediately visible in the pricing debates we typically focus on.

Marcus"That's fair, though I think payers would see it differently. From a system sustainability perspective, this might actually be a necessary recalibration. The question is whether we're seeing a temporary adjustment or a permanent structural shift in how innovative therapies are valued and reimbursed in the US market.

Sara"What's striking here is the timing. This emerges as we're seeing increased scrutiny from both regulators and payers on drug pricing and value demonstration. It suggests that the traditional pathways for market access may be fundamentally changing, requiring new evidence generation strategies.

Marcus"I keep coming back to the patient perspective here. When hospital systems face financial constraints, it's often the patients with complex conditions who bear the brunt. This creates an interesting tension between system sustainability and patient access that we'll need to navigate carefully.

Sara"This is one of those stories where the financial metrics are telling us something important about the underlying healthcare system dynamics. I'll be watching how other hospital systems respond and whether this becomes a broader trend.

Marcus"Moving to subcutaneous Leqembi — this approval fundamentally changes the Alzheimer's treatment landscape. The administration burden reduction is significant, but more importantly, it creates new evidence requirements for payers assessing value in this space.

Sara"Honestly, this one caught me off guard. While the subcutaneous formulation clearly addresses a key barrier to adoption, the fundamental value question for Alzheimer's treatments remains unchanged. We still lack clear evidence of meaningful functional benefits that align with traditional value frameworks.

Marcus"That's a crucial point. The formulation change might improve uptake, but it doesn't address the core evidence gaps that have made these treatments challenging for HTA bodies to recommend. What's interesting is how this might shift the evidence generation strategy toward real-world data showing impact on caregiver burden and healthcare utilization.

Sara"The part that gives me pause is the budget impact equation. Even with improved administration, these therapies remain extremely high-cost. Payers will need to see clear evidence of reduced downstream healthcare costs to justify the investment, which remains a significant hurdle.

Marcus"I wonder if that's the full picture though. The subcutaneous formulation might actually enable more personalized treatment approaches, potentially improving outcomes through better adherence. This could create new value pathways that haven't been fully explored in previous assessments.

Sara"What strikes me is how this connects to the broader Alzheimer's treatment ecosystem. With multiple approved therapies now available, the conversation is shifting from individual drug assessment to comparative effectiveness and sequencing strategies, which adds another layer of complexity for HEOR teams.

Marcus"This approval definitely reshapes the value narrative, but the fundamental questions about cost-effectiveness and system impact remain. I'll be watching how payers incorporate this new formulation into their coverage decisions and whether it leads to more favorable reimbursement pathways.

Sara"Now, the FTC-CVS insulin settlement. This is significant because it directly addresses some of the most controversial practices in the insulin supply chain. The settlement specifically targets the spread pricing practices that have contributed to high out-of-pocket costs for patients.

Marcus"That's one read — I'd frame it slightly differently. While the settlement addresses spread pricing, it's the broader implications for PBM practices that matter most. This settlement signals increased regulatory scrutiny of PBM business models, which could fundamentally reshape how insulin and other high-cost medications are priced and distributed in the US market.

Sara"The part that gives me pause is whether this represents a meaningful change or just a tactical adjustment. The settlement doesn't address the underlying structural issues with PBM practices, particularly the lack of transparency in rebate structures and formulary placement decisions.

Marcus"What strikes me is how this connects to the broader insulin access debate. While this settlement might reduce some immediate cost pressures, it doesn't solve the fundamental question of how to ensure sustainable access to insulin for all patients who need it. The focus remains on cost shifting rather than value-based pricing models.

Sara"That's fair, though I think this could be a precedent-setting moment. The FTC's willingness to challenge these practices suggests that regulatory oversight of PBMs is increasing, which could lead to more meaningful reforms in how pharmaceutical benefits are managed.

Marcus"I keep coming back to the patient perspective here. While this settlement might reduce some costs, it doesn't address the core issue of insulin affordability for patients with high deductibles or those in the coverage gap. The real solution will require more fundamental reforms to how we value and reimburse essential medications.

Sara"This settlement exposes the complex web of relationships between manufacturers, PBMs, and payers that has driven insulin prices higher. I'll be watching how this settlement is implemented and whether it leads to more transparent pricing practices across the board.

Marcus"Finally, ICER's early-phase scientific advice expansion. This is a significant development that could fundamentally reshape how companies approach evidence generation in the early stages of development.

Sara"Honestly, this one caught me off guard. While early-phase advice isn't new, ICER's expansion of this service suggests a recognition that evidence generation needs to begin earlier in the development process. What's striking is how this could help de-risk development by providing earlier clarity on value expectations.

Marcus"That's a crucial point. This expansion reflects a broader shift toward value-based development, where evidence generation is aligned with payer expectations from the outset. It could help reduce the high failure rates in late-stage development by ensuring that compounds have the right evidence profile for market access.

Sara"The part that gives me pause is how this interacts with traditional regulatory pathways. While early-phase advice can provide valuable insights, it doesn't replace the need for robust clinical evidence. There's a risk of creating unrealistic expectations about what can be achieved with limited data.

Marcus"I wonder if that's the full picture though. This approach could actually accelerate innovation by helping companies focus resources on the most promising candidates and evidence gaps. It represents a more collaborative approach to evidence generation that could benefit both industry and payers.

Sara"What strikes me is how this connects to the broader HEOR landscape. As payers increasingly demand evidence of real-world value, early-phase advice could help companies design more pragmatic trials that generate the kind of evidence that matters for coverage decisions.

Marcus"This expansion definitely aims to de-risk development, but the fundamental question remains whether it can provide meaningful guidance in the face of significant uncertainty. I'll be watching how companies incorporate this advice into their development strategies and whether it leads to more successful market access outcomes.

Sara"A lot to think about today. I'll be watching how HCA's profit warning impacts broader hospital system strategies for innovative therapies, particularly as we approach the next round of formulary decisions.

Marcus"Same — and for me the thread running through today is how market access is becoming increasingly complex across all stakeholders. We're seeing fundamental shifts in how value is demonstrated and negotiated, requiring more sophisticated evidence strategies.

Sara"Thanks so much for listening — really glad you're here with us.

Marcus"We'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

Sara"Thanks for listening — see you tomorrow.

Marcus"Back tomorrow on Access Brief. Show notes at outcomes-analytica.no."